Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kyorin: Ethical Drug Sales Down 5.7% to \51.5 Bil.
June 7, 2004
- GVP, GQP GLs to Be Announced in July
June 7, 2004
- Mochida: Profits Down Sharply due to Increase in Investment Costs
June 7, 2004
- REGULATORY NEWS IN BRIEF
June 7, 2004
- Zeria: Sales Down 1.2% to \54.3 Bil.
June 7, 2004
- PRESS SEMINR
June 7, 2004
- Nikken Chemicals: Drug Division Sales Down 3.8% to \41.2 Bil.
June 7, 2004
- OTC NEWS IN BRIEF
June 7, 2004
- Nippon Shinyaku: Drug Division Sales Down 4.4% to \42.4 Bil.
June 7, 2004
- Annual Business Results
June 7, 2004
- Fuso: 1st Increase in Ordinary Profits in 3 Years
June 7, 2004
- DIAGNOSTIC NEWS IN BRIEF
June 7, 2004
- Teikoku Hormone: Drug Division Sales Slip 4.1% to \18.6 Bil.
June 7, 2004
- Annual Business Results
June 7, 2004
- Sumitomo Pharmaceuticals: Sales Fall 1% to \136.9 Bil.
June 7, 2004
- Semiannual Business Results
June 7, 2004
- JPMA to Help Industry Contribute to Global Healthcare: Dr Aoki
June 7, 2004
- Towa Yakuhin: Sales of \23.1 Bil. Make It No.1 GE Maker
June 7, 2004
- Takara Bio Reports Antithrombotic Action of Fucoidan Oligosaccharides
June 7, 2004
- Annual Business Results
June 7, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…